Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO6807952 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Placebo to RO6807952 |
| RO6807952 | DRUG | Escalating subcutaneous dose |
Inclusion Criteria: * Adult patients, 18 to 70 years of age, inclusive * Diagnosis of type 2 diabetes \>/=3 months and \</=10 years prior to screening * Fasting plasma glucose \>/=110 mg/dL and \</=240 mg/dL * Patients on a stable dose of metformin for at least 2 months prior to screening * Hemoglo...
RO6807952 is an investigational small molecule being studied for the treatment of Diabetes Mellitus Type 2. It is in Phase 1 clinical development and is not yet approved for any use.
RO6807952 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Type 2 diabetes.
RO6807952 is in Phase 1 clinical development. A Phase 1 study has been completed, but the drug remains investigational and has not been approved by regulatory authorities.
RO6807952 has one completed clinical trial, NCT01358929, which was a Phase 1 study in patients with Diabetes Mellitus Type 2. The trial enrolled 45 participants in the United States and was randomized, double-blind, and placebo-controlled.
RO6807952 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development, and its safety and efficacy have not been established for the treatment of Type 2 diabetes.